Effect of Premorbid Beta-Blockers on Mortality in Patients With Sepsis: A Systematic Review and Meta-Analysis

Abstract

Objective

The aim of this study was to conduct a systematic review and meta-analysis to investigate the impact of premorbid beta-blockers on mortality in patients with sepsis.

Data Sources

We searched EMBASE, the Cochrane Central Register of Controlled Trials, and MEDLINE for eligible studies. The protocol was registered at the PROSPERO (CRD42021256813).

Study Selection

Two authors independently evaluated the following inclusion criteria: (1) randomized controlled trials, cohort studies, cross-sectional studies; (2) patients with sepsis aged ≥18 years, and (3) premorbid beta-blocker use.

Data Extraction

Two authors extracted the patients’ characteristics and outcomes independently. All analyses were performed using the random-effects models. The primary outcome was short-term mortality, defined as mortality within 30 days, in-hospital or intensive care unit mortality.

Data Synthesis

Ten studies (n = 24 748 patients) were included. The pooled odds ratio (OR) of short-term mortality associated with the premorbid use of beta-blockers was 0.85 (95% confidence interval [CI], 0.69-1.04; P = .12; I² = 50%). Five studies reported an adjusted OR of short-term mortality. The pooled adjusted OR of short-term mortality associated with the premorbid use of beta-blockers was 0.73 (95% CI, 0.65-0.83; P < .001; I² = 0%).

Conclusion

Premorbid beta-blockers were associated with a lower short-term mortality in patients with sepsis.

Keywords

sepsis beta-blocker adrenergic mortality meta-analysis

Get full access to this article

View all access options for this article.

References

Angus

van der Poll

. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840‐851.

de Montmollin

Aboab

Mansart

Annane

. Bench-to-bedside review: Beta-adrenergic modulation in sepsis. Crit Care. 2009;13(5):230.

Leibovici

Gafter-Gvili

Paul

, et al. Relative tachycardia in patients with sepsis: an independent risk factor for mortality. Qjm. Oct 2007;100(10):629‐634.

Ali

O‘Brien

Jr. Dungan

, et al. Glucose variability and mortality in patients with sepsis. Crit Care Med. 2008;36(8):2316‐2321.

Lyons

Micek

Hampton

Kollef

. Sepsis-associated coagulopathy severity predicts hospital mortality*. Crit Care Med. 2018;46(5):736‐742.

Sato

Ariyoshi

Hasegawa

, et al. Effects of inotropes on the mortality in patients with septic shock. J Intensive Care Med. 2019:885066619892218.

Hasegawa

Sato

Prasitlumkum

, et al. Effect of ultrashort-acting β-blockers on mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: A systematic review and meta-analysis of randomized controlled trials. Chest. Jun 2021;159(6):2289‐2300.

Tan

Harazim

Tang

McLean

Nalos

. The association between premorbid beta blocker exposure and mortality in sepsis—a systematic review. Crit Care. 2019;23(1):298.

Kuo

Chou

Huang

Lin

. Premorbid, cardioselective beta-blocker exposure decreases ICU mortality in septic patients defined by sepsis-3. Eur Heart J. 2020;41(Supplement_2).

10.

Tan

Harazim

Simpson

, et al. Association between premorbid beta-blocker exposure and sepsis outcomes—the beta-blockers in European and Australian/American septic patients (BEAST) study. Crit Care Med. 2021; Latest Articles.

11.

Moher

Liberati

Tetzlaff

Altman

Group

. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264‐269. W264.

12.

Ouzzani

Hammady

Fedorowicz

Elmagarmid

. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.

13.

Bone

Balk

Cerra

, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644‐1655.

14.

Levy

Fink

Marshall

, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250‐1256.

15.

Singer

Deutschman

Seymour

, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801‐810.

16.

Stang

. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603‐605.

17.

Wan

Wang

Liu

Tong

. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.

18.

Higgins

Thompson

. Quantifying heterogeneity in a meta-analysis. Stat Med. 15 2002;21(11):1539‐1558.

19.

Macchia

Romero

Comignani

, et al. Previous prescription of β-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med. 2012;40(10):2768‐2772.

20.

Contenti

Occelli

Corraze

Lemoël

Levraut

. Long-term β-blocker therapy decreases blood lactate concentration in severely septic patients. Crit Care Med. 2015;43(12):2616‐2622.

21.

Arnautovic

Mazhar

Souther

Mikhijan

Boura

Huda

. Cardiovascular factors associated with septic shock mortality risks. Spartan Med Res J. 2018;3(1):6516.

22.

DeMott

Patel

Lat

. Effects of chronic antihypertensives on vasopressor dosing in septic shock. Ann Pharmacother. 2018;52(1):40‐47.

23.

Chan

JZW

Tan

Lather

, et al. Beta-blockers’ effect on Levels of Lactate in patients with suspected sepsis—The BeLLa study. Am J Emerg Med. 2020;38(12):2574‐2579.

24.

Pham

Ward

Yong

, et al. Is lactate lower in septic patients who are prescribed beta blockers? Retrospective cohort study of an intensive care population. Emerg Med Australas. 2021;33(1):82‐87.

25.

Guz

Buchritz

Guz

, et al. Beta-blockers, tachycardia and survival following sepsis—an observational cohort study. Clin Infect Dis. 2021.

26.

Hasegawa

Sato

Nishida

. β1-blocker in sepsis. J Intens Care. 2021;9(1):39.

27.

Vieillard Baron

Schmitt

Beauchet

, et al. Early preload adaptation in septic shock? A transesophageal echocardiographic study. Anesthesiology. 2001;94(3):400‐406.

28.

Morelli

Ertmer

Westphal

, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310(16):1683‐1691.

29.

Gattinoni

Vasques

Camporota

, et al. Understanding lactatemia in human sepsis. Potential impact for early management. Am J Respir Crit Care Med. 2019;200(5):582‐589.

30.

Garcia-Alvarez

Marik

Bellomo

. Sepsis-associated hyperlactatemia. Crit Care. 2014;18(5):503.

31.

Levy

Fritz

Piona

, et al. Hemodynamic and anti-inflammatory effects of early esmolol use in hyperkinetic septic shock: a pilot study. Crit Care. 2021;25(1):21.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

1.02 MB

0.42 MB